C反应蛋白与静脉血栓栓塞的遗传预测因素与重型2019冠状病毒病结局的关联
该回顾性队列研究基于U.K. Biobank,纳入2020年3月16日至8月14日间SARS-CoV-2 PCR检测阳性的欧洲血统参与者1126例,分别构建C反应蛋白(56个遗传变异)和静脉血栓栓塞(37个遗传变异)的遗传风险评分。结果显示,48%因COVID-19住院,16%接受重症监护支持,10%接受关键呼吸支持,21%死于COVID-19。C反应蛋白高浓度的遗传易感与COVID-19死亡风险呈边缘性负相关(OR 0.85,95%CI 0.73-1.00,P=0.05),其余关联均无统计学意义。作者结论认为,C反应蛋白浓度升高或静脉血栓栓塞风险的多基因风险与重型COVID-19健康结局无关,不适用于预测重型COVID-19结局。
要点
- 在1126例PCR确诊COVID-19的欧洲血统U.K. Biobank参与者中,48%住院、16%接受重症监护支持、10%接受关键呼吸支持、21%死于COVID-19。
- C反应蛋白高浓度的遗传易感与COVID-19死亡风险呈边缘性负相关(OR 0.85,95%CI 0.73-1.00,P=0.05)。
- 静脉血栓栓塞遗传风险评分与重型COVID-19结局均无显著关联。
- 作者结论:C反应蛋白浓度或静脉血栓栓塞风险的遗传易感对预测重型COVID-19健康结局无意义。
适用人群与场景
- U.K. Biobank中记录为SARS-CoV-2 PCR检测阳性的欧洲血统参与者,检测阳性时间在2020年3月16日至2020年8月14日之间。
研究设计与关键结果
- 研究类型:回顾性队列研究;数据来源:U.K. Biobank;样本量:1126例PCR确诊COVID-19的欧洲血统参与者。
- 分别构建C反应蛋白遗传风险评分(56个遗传变异)和静脉血栓栓塞遗传风险评分(37个遗传变异)。
- 队列结局:48%因COVID-19住院,16%接受重症监护支持,10%接受关键呼吸支持,21%死于COVID-19。
- C反应蛋白高浓度的遗传易感与COVID-19死亡风险呈边缘性负相关(OR 0.85,95%CI 0.73-1.00,P=0.05)。
- 其余关联均无统计学意义。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 作者结论:结果不支持C反应蛋白浓度升高或静脉血栓栓塞的多基因风险与重型COVID-19健康结局存在关联,因此考虑C反应蛋白浓度或静脉血栓栓塞风险的遗传易感对预测重型COVID-19健康结局无意义。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,考虑C反应蛋白浓度或静脉血栓栓塞风险的遗传易感对预测重型COVID-19健康结局无意义。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To assess if genetic predictors for C-reactive protein and risk of venous thromboembolism are associated with severe outcomes among individuals who tested positive for severe acute respiratory syndrome coronavirus 2.
DESIGN: Retrospective cohort study.
SETTING: U.K. Biobank.
PATIENTS OR SUBJECTS: U.K. Biobank participants with European ancestry who were recorded to have a positive polymerase chain reaction test result for severe acute respiratory syndrome coronavirus 2 between March 16, 2020, and August 14, 2020.
INTERVENTIONS: Not applicable.
MEASUREMENTS AND MAIN RESULTS: We constructed separate genetic risk scores for C-reactive protein and venous thromboembolism consisting of 56 and 37 genetic variants that have been significantly associated with venous thromboembolism and C-reactive protein, respectively. Among 1,126 individuals who were diagnosed with coronavirus disease 2019, 48% had a coronavirus disease 2019-related hospitalization, 16% received critical care support, 10% had critical respiratory support, and 21% died from coronavirus disease 2019. Genetic predisposition to high C-reactive protein concentrations was marginally associated with a lower risk of death from coronavirus disease 2019 (odds ratio, 0.85; 95% CI, 0.73-1.00; p = 0.05). No other associations were significant.
CONCLUSIONS: Our results do not support associations between polygenic risk for elevated blood C-reactive protein concentrations or venous thromboembolism and severe coronavirus disease 2019 health outcomes. Thus, considering genetic predisposition associated with C-reactive protein concentrations or venous thromboembolism risk is not meaningful for predicting severe coronavirus disease 2019 health outcomes.
参考来源
- Guo B, Williams-Nguyen J, Wang L, et al. Association Between Genetic Predictors for C-Reactive Protein and Venous Thromboembolism With Severe Adverse Coronavirus Disease 2019 Outcomes. Crit Care Explor. 2021. PMID: 34957408. doi:10.1097/CCE.0000000000000602
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。